Year-end report 2024

alzinova

We will make it possible for Alzheimer's patients to live an *independent and active life.*

Highlights during the period

Positive results from the extension part of the phase 1b study

Alzinova reported continued promising results from its phase 1b clinical study with the vaccine candidate ALZ-101.

The participation at JP Morgan

Alzinova attended the J.P. Morgan Healthcare Conference in San Francisco. The management met with a large number of potential partners and investors to present the company's latest positive Alzheimer's clinical data and strong results from the phase 1b study of the vaccine candidate ALZ-101.

All study participants have completed the final visit in the phase 1 study

Alzinova announced that all study participants have completed the final visit in the Phase 1 study. The final results for the entire study period are planned to be available by the end of March 2025.

Key figures from the period

THREE MONTHS, OCTOBER–DECEMBER, 2024

- Net sales amounted to SEK 0 thousand (0).
- Loss after financial items amounted to SEK -6 563 thousand (-4,731).
- Average number of shares during the period amounted to 89,165,460 (44,531,265).
- Earnings per share amounted to SEK -0.07 (-0.11).

TWELVE MONTHS, JANUARY–DECEMBER, 2024

- Net sales amounted to SEK 0 thousand (0).
- Loss after financial items amounted to SEK -20,553 thousand (-16,480).
- Average number of shares during the period amounted to 66,793,687 (40,383,241).
- Earnings per share amounted to SEK -0.31 (-0.41).

There are no dilution effects regarding the number of shares.
Amounts in brackets: Corresponding period in previous year.
"the Company" or "Alzinova" refers to Alzinova AB with corporate identity number: 556861-8168.

Significant events during the fourth quarter 2024

- All patients in the high dose part (part A2) of the phase 1b study received their last dose.
- Alzinova announced that patient data from the extension part of the phase 1b study with ALZ-101 is being processed. Results are expected around the end of November-December 2024.
- The company participated in BIO-Europe 2024, one of Europe's largest partnering conferences in life science, where it met a large number of potential partners.
- Alzinova reported continued promising results from its phase 1b clinical trial with the vaccine candidate ALZ-101 in Alzheimer's disease. Analysis of data from patients who participated in the study for at least 84 weeks showed, among other things, that ALZ-101 continues to have a good tolerability and safety profile. The positive results provide strong support for continued clinical development of ALZ-101.
- Alzinova appointed Erik Kullgren as permanent CFO, after he served as interim CFO since March 2024.

Significant events after the end of the fourth quarter 2024

- Alzinova participated between January 13-16, 2025 at the J.P. Morgan Healthcare Conference in San Francisco, where management met with a large number of potential partners and investors to present the company's latest positive clinical Alzheimer's data and strong results from the phase 1b study with the vaccine candidate ALZ-101.
- The Company announced that a strategic decision has been made to appoint a CMO on site at the Company's head office in Gothenburg, primarily with the aim of being able to maintain even closer dialogue with the business's R&D team and management team as Alzinova enters the next development phase.
- Alzinova announced that all study participants have completed the final visit in the phase 1 study. All data points will then be processed, analyzed and compiled. The final results for the entire study period are planned to be communicated by the end of March 2025.

A word from CEO Tord Labuda

Strong position for the next phase

Dear Shareholders,

As we have now completed 2024 and looking ahead, I am pleased to report on significant progress in our clinical development and a strengthened position for Alzinova AB. With undiminished enthusiasm and strategic determination, we continue our journey towards phase 2 studies and further towards the market.

Alzinova is an innovative player in the treatment of Alzheimer's disease with a unique, oligomer-specific immunotherapy that represents a paradigm shift in the field. Our selective approach targets the most harmful amyloid-beta molecules, the oligomers, which distinguishes us from other antibody treatment methods. Our work during the year has cemented our role as a leading player in Alzheimer's research, and the results we have achieved strengthen our conviction in ALZ-101's potential as a breakthrough treatment for Alzheimer's disease.

Milestones and clinical progress

We are in the final phase of our phase 1b study with ALZ-101. The results from the extension part (B) after 42 weeks confirm our previous analysis, with an excellent safety profile and a strong immune response. In addition, our cognitive data indicate that ALZ-101 can have a real effect on the course of the disease, which would be revolutionary if verified in a larger phase 2 study.

The high-dose part (A2) of the study has now also been successfully completed, confirming the safety profile, the tolerability, and the robust immune respons, which gives us valuable insight for phase 2. The remaining analyses, including immune responses and biomarkers from the overall study and the results will be presented in a press release at the end of March 2025. We look forward to the opportunity to share our progress at the next major global scientific Alzheimer-conference, AAIC in Toronto in July, which is an important platform to reach out to potential partners and investors.

Preparations for phase 2

Preparations for the phase 2 study are progressing according to plan. On the regulatory side, we expect to apply for an IND followed by Fast Track in the US, in parallel with PRiME (the European equivalent of Fast Track) in the EU in Q3. In the same way, we are in the final phase of the production of study substance in collaboration with our partners and expect to be ready well in advance of the start of the study. This work is critical to ensure a smooth transition to the next phase of our clinical program, thereby maximizing the chances of success.

Financial position and partnership

Through this summer's oversubscribed rights issue, we have been able to drive both clinical development and preparations for phase 2 forward during the autumn with a maintained pace. We are

"Our work over the year has cemented our role as a leader in Alzheimer's research, and the results we have achieved reinforce our belief in ALZ-101's potential as a breakthrough treatment for Alzheimer's disease."

actively evaluating various financing options for the phase 2 study, including potential strategic partnerships and traditional capital raises. The J.P. Morgan conference in January, where we presented our latest clinical data, was a great success. This has led to follow-up meetings with several of the major pharmaceutical companies we met during the conference in San Francisco, and we have high hopes of finding a good partner in the near future who can support our continued development through phase 2 and further towards the market. Securing funding is also crucial to fully invest in conducting the crucial toxicological studies in the near future in order to be able to take ALZ-201 (our antibody treatment) into clinical studies.

ALZ-101: A potential game-changer

ALZ-101 continues to show great potential as a game-changer and best-in-class in Alzheimer's treatment. Its unique mechanism of specifically targeting the neurotoxic accumulations of amyloid-beta peptides, so-called oligomers, positions us well in a field where truly effective disease-modifying treatments are conspicuous by their absence. The current antibody treatments against amyloid-beta are struggling with low effectiveness, high costs and serious side effects. With its unique mechanism, ALZ-101 has the potential to open up completely new opportunities for the company and millions of patients worldwide. Positive results from our ongoing and future studies could revolutionize Alzheimer's treatment.

Future prospects and closing words

Our main priority going forward is to accelerate our clinical development program. We are facing exciting times with groundbreaking results and opportunities to make a real difference in the fight against Alzheimer's disease.

I look forward to building on Alzinova's success together with our dedicated and knowledgeable team. With our shared innovation and passion, we are ready to meet the challenges ahead and create long-term value for our shareholders, employees and above all for patients and their families living with Alzheimer's disease. Thank you for your continued support and trust.

Gothenburg, February 2025

Tord Labuda,
CEO of Alzinova AB

Investment highlights

Vaccine with potential to treat Alzheimer's

Alzinova's lead candidate, ALZ-101, is a therapeutic vaccine for the treatment of Alzheimer's disease. ALZ-101 is in the final phase of a phase 1b clinical trial and has demonstrated good safety and tolerability, among other things.

Complementary treatment with Best-in-Class antibody

Based on the same technology, Alzinova is also developing a monoclonal antibody, ALZ-201, as a complementary treatment to the vaccine to combat Alzheimer's disease.

Best-in-class potential with favourable safety profile

Data shows that the unique specificity of Alzinova's vaccine (ALZ-101) and monoclonal antibody (ALZ-201) has the potential for "best in class" with greater efficacy and a more favorable side effect profile than other treatments.

Regulatory progress boost collaborations

Positive feedback from the FDA and EMA, as well as other ongoing activities leading up to the next clinical development phase, make Alzinova's candidates attractive for strategic partnerships.

Enables an independent and active life

About Alzinova

Alzinova AB is a Swedish biopharmaceutical company specializing in the treatment of Alzheimer's disease. The company's patented AβCC peptide technology™ enables the development of disease-modifying treatment with the potential to neutralize the accumulations of neurotoxic Abeta peptides, so-called oligomers, that are central to the onset and development of Alzheimer's disease.

With this technology, Alzinova can develop effective treatments that at the same time have a beneficial profile with a lower risk of side effects compared to other treatments. Preclinical results have previously (study on brain extracts from deceased Alzheimer's patients) confirmed that Alzinova's unique method works.

The vaccine candidate ALZ-101 is currently under clinical development, with a phase 1b study in Alzheimer's patients that started in Q3 2021. At the end of January 2025, the last patient visit in the phase 1b study was conducted. All the collected data is now being processed, analyzed and compiled to be reported by the end of March 2025.

The primary objective of the study was to evaluate the safety and tolerability of repeated dosing of the ALZ-101 vaccine candidate in patients with early Alzheimer's disease. The study also includes secondary and exploratory endpoints related to immune response, cognition, and biomarkers.

The phase 1b study includes a total of 32 patients with early Alzheimer's disease. The study has examined three different dose strengths of ALZ-101, 125, 250 and 400 µg as well as placebo. 26 patients were treated double-blindly and randomized with the ALZ-101 vaccine at doses of 125 µg or 250 µg and six patients with placebo. Of these 26 patients, 23 patients continued in an extension phase, which meant that all patients received open-label treatment with 250 µg ALZ-101 over a 20-week period and with an additional 48 weeks of follow-up.

The primary purpose of the extension part is to provide information on long-term safety, tolerability, the long-term immune response, and information on the effect on cognitive parameters and biomarkers.

Six additional patients were enrolled to investigate whether higher dose, 400 µg ALZ-101, has the same safety and tolerability as lower doses, and whether secondary endpoints are met to a greater extent. The patients were treated on four occasions at the same intervals as in the other treatment groups. These patients were followed for a total of 20 weeks.

Previously, positive results from part of the extension part have been reported and by the end of March 2025, the total study results are expected to be fully analyzed.

Based on the same AβCC peptide technology, the Company is also developing the antibody ALZ-201, which is currently in preclinical development. The project portfolio for the development of disease-modifying therapies is broadened by the Company preparing the antibody for clinical development. Alzinova was founded by researchers who worked at the MIVAC research center at the University of Gothenburg, and by GU Ventures AB.

Alzheimer's disease

In Alzheimer's disease, the nerve cells in the brain are damaged by abnormal protein deposits that mainly consist of amyloid-beta 42 (Aβ42), a type of small protein that also occurs in a healthy brain. When the Aβ42 molecule clumps together, stable accumulations are formed in the brain, plaques, but also so-called oligomers.

Oligomers differ structurally from the plaque and, unlike the plaque, are highly toxic to brain cells. They damage important functions that make the contact surfaces between the nerve cells, the synapses, stop working normally. Synapses are the places in the brain where electrical and chemical signals are transmitted from one nerve cell to another, and their function is critical to our ability to remember, react, think and act. Eventually, due to synaptic impairment, the nerve cell dies.

The disease first affects the parts of the brain that handle short-term memory, but eventually the disease spreads over the entire brain and the patient finds it increasingly difficult to carry out daily tasks. In the end, the patient cannot manage on their own, but requires care and continuous monitoring.

Alzheimer's is a disease that basically anyone can get, and which is strongly age-dependent. Over 95% of all cases affect those over the age of 65, and in these cases there is not a strong genetic component driving the disease.

Alzheimer's is most common in the elderly population, with 1 in 9 people over 65 affected, 65% of whom are women. However, about 5% of cases are diagnosed at an earlier age.



Business model

Alzinova's business model is to drive projects into clinical development with the aim of documenting that the drug candidates are safe and well tolerated as well as demonstrating proof-of-concept, i.e. that they exhibit efficacy in patients with Alzheimer's disease. Based on positive clinical data, the Company has identified several potential strategic partners who have the resources and in-house expertise to conduct the studies needed for registration and commercialisation. This can be done through out-licensing with a partnership where the Company jointly brings the drug to the market with the collaboration partner, or by selling the drug candidate for further development.

Out-licensing

A common alternative for development companies like Alzinova is to out-license projects to one or more pharmaceutical companies. Either these can get exclusivity in a limited market, and you agree with several partners to cover the market globally, or you have a global partner who takes the drug to the entire market. A typical arrangement for out-licensing is initial compensation and then future installments linked to pre-defined milestones during further development, the regulatory process and commercialization with high revenues linked to future drug sales.

The Company has so far taken several important steps towards out-licensing and commercialization. The data shows "best-in-class" potential, which is very attractive for partnering. With positive results in the Company's two drug projects, ALZ-101 and ALZ-201, there are several options. One is to out-license the ALZ-101 vaccine to a major pharmaceutical company, and another option is for Alzinova to take ALZ-101 through phase 2 and then out-license it to a partner. For the antibody ALZ-201, this could be out-licensed immediately during the preclinical phase, or alternatively after phase 1b studies. The Company's focus going forward is on business development with several ongoing dialogues in parallel with clinical development of the project portfolio.

Market

Every year around 10 million people in the world become ill with some form of dementia, of which Alzheimer's disease accounts for around 60-70 %. Today, it is estimated that there are approximately 55 million patients with dementia in the world, but it is difficult to diagnose dementia today at early stages of disease. Therefore, it is expected that this figure is significantly higher. In addition, this number is expected to increase to more than 130 million by 2050. It is estimated that more than 30 million people in the world today have Alzheimer's disease and the number is expected to triple by 2050[1].

The societal costs of dementia diseases are currently estimated at $1,300 billion annually[2]. The drug cost of Alzheimer's medications, which are symptom relief alone, amounts to approximately $6 billion annually. While the first disease-modifying drugs have recently been approved in the United States, Japan and China there is still a very long way to go to truly treat and prevent the progression of Alzheimer's disease.

The sales and revenue potential of a new effective disease-modifying drug is therefore significant even if it would only have an initially limited market share. By 2026, drugs for Alzheimer's disease are expected to be represented among 2 out of 7 expected top sellers (pharmaceutical companies), with an expected annual turnover of USD 1.7-4.5 billion[3]. The reason why the initial sales estimates are relatively low is that there have been no good medical alternatives. With effective treatment options coming to the market, such as Alzinova's drug, the Company estimates that annual sales can be multiplied several times compared to today.

The research firm Global Data estimates that annual sales for disease-modifying drugs for Alzheimer's disease will reach roughly $13 billion by 2028 in the largest markets: the United States, Germany, France, the United Kingdom, Italy, Spain, Japan, China, and India. An approved disease-modifying treatment for Alzheimer's disease has the potential to generate peak annual sales in excess of USD 10 billion[4].

1) World Health Organization (WHO) – Facts about Dementia, March 2023
2) World Alzheimer's Report, 2024.
3) Drugs to watch report, 2022.
4) US, Germany, France, UK, Italy, Spain, Japan, China. GlobalData, Pharma, June 7, 2023.

Alzinova's competitive advantages



Based on statistics from Statistics Sweden (SCB) about the Swedish healthcare system, and that the two treatments have equivalent clinical efficacy, total treatment duration and drug cost.

Alzinova is developing a vaccine candidate to treat Alzheimer's disease. The vaccine, unlike other treatments such as antibodies, is expected to require only a few doses a year rather than as often as every two weeks. In addition, it can be given to patients in a very time-efficient way through a simple injection in primary care or at home by a nurse. Other treatments are time-consuming and require hospital care.

To treat patients with therapeutic antibodies, this sharply increases societal costs, resulting in fewer patients being treated with an antibody treatment. With Alzinova's vaccine, compared to antibody treatment, healthcare and societal costs can be reduced, which creates the opportunity for more people to receive treatment.

Financial information

Corporate structure and shareholding
Alzinova has no subsidiaries and is not part of any group. Neither does the Company hold any shares.

Financial development – fourth quarter 2024
During the period October - December, the Company has continued to invest in the further development of ALZ-101, which is in the final part of a clinical phase 1b study. The Company also continues to invest in preparations for clinical phase 2 and in preparations for clinical studies of the antibody ALZ-201.

The company's total costs during the fourth quarter of 2024 amounted to 11,882 (10,696) thousand SEK. Of the costs for the period, 5,302 (5,613) thousand SEK relates to research and development (R&D) costs, including costs for the finalization of the clinical study, as well as preparations for the production of the drug substance prior to the start of the upcoming clinical phase 2 study. The company's R&D costs have been capitalized in the balance sheet. Of the total costs, personnel costs during the period amounted to 2,946 (3,106) thousand SEK.

Cash flow from operating activities during the fourth quarter amounted to -6,876 (-5,265) thousand SEK. Cash flow from investing activities consists of expenses for continuously capitalized R&D costs and amounted to -5,302 (-5,613) thousand SEK during the same period. Cash flow from financing activities amounted to 0 (0) thousand SEK.

Financial development – full year 2024
For the period January-December 2024, the Company's total costs amounted to 37,193 (36,396) thousand SEK.

Cash flow from operating activities for the full year 2024 amounted to -20,265 (-15,213) thousand SEK. The lower cash flow during the period is due to higher costs for R&D, mainly preparations for the production of substance for the start of the upcoming clinical phase 2 study. Cash flow from investing activities amounted to -16,781 (-19,604) thousand SEK. Cash flow from financing activities amounted to 30,517 (24,805) thousand SEK where shares were issued through a rights issue registered during the third quarter of 2024.

Financial position
At the end of the period, the Company's equity amounted to approximately 123,823 (113,858) thousand SEK with an equity/assets ratio of 92.9% (92.4%), and total cash balances amounted to approximately 15,496 (22,026) thousand SEK. There is continuous work on various strategic financing alternatives. To further strengthen the Company's position and to secure liquidity in the short term and the working capital requirement, the Company has received a binding promise of temporary financing on market terms through Maida Vale Capital AB, the Company's single largest owner.

Proposal for profit allocation
The board of directors proposes no dividend for the 2024 financial year and that available disposable funds be carried forward.

Rights issue
During the year, the Company completed an oversubscribed rights issue, which raised a total of SEK 30.5 million for the Company after deduction of issue costs. The number of shares in Alzinova subsequently amounts to 89,165,460 shares, with a total share capital of SEK 23,450,516. For shareholders who did not participate in the rights issue, the dilution amounted to approximately 50% based on the total number of shares in the Company.

Risk factors
A detailed assessment of the Company's uncertainty factors was included in the Annual Report 2023 and in the prospectus published in connection with the rights issue in June 2024.

Auditor's review
This report has not been reviewed by the Company's auditors.

Policies for the preparation of the interim financial report
The interim financial report is prepared in accordance with the Swedish Annual Accounts Act as well as the Swedish Accounting Standards Board BFNAR 2012:1 annual report and consolidated (K3).

The Board of Directors and the Chief Executive Officer hereby confirm that this interim report provides a true and fair view of the Company's operations, financial position and earnings, and describes significant risks and uncertain factors the Company is facing.

Mölndal, February 27, 2025
Alzinova AB (publ)

Income statement

(TSEK)	2024-10-01 2024-12-31 3 months	2023-10-01 2023-12-31 3 months	2024-01-01 2024-12-31 12 months	2023-01-01 2023-12-31 12 months
Net sales	-	-	-	-
Other revenues	0	270	30	270
Own work capitalized	5,302	5,613	16,781	19,604
	5,302	5,883	16,811	19,874
Operating expenses				
Other external expenses	-8,939	-7,590	-26,665	-27,097
Personnel expenses	-2,946	-3,106	-10,528	-9,299
Operating result	**-6,581**	**-4,813**	**-20,381**	**-16,522**
Result from financial items				
Interest income	63	139	65	140
Interest expenses	-46	-57	-236	-98
Result after financial items	**-6,563**	**-4,731**	**-20,553**	**-16,480**
Result before tax	**-6,563**	**-4,731**	**-20,553**	**-16,480**
Result for the period	**-6,563**	**-4,731**	**-20,553**	**-16,480**

Balance sheet

(TSEK)	31 Dec 2024	31 Dec 2023
ASSETS		
Fixed assets		
Intangible assets		
Capitalized expenditure for development work	113,035	96,253
Patent	1,632	1,632
	114,667	**97,885**
Total fixed assets	**114,667**	**97,885**
Current assets		
Short term receivables		
Tax receivables	273	257
Other receivables	412	378
Prepaid expenses and accrued income	2,379	2,643
	3,063	**3,278**
Cash and cash receivables	**15,496**	**22,026**
Total current assets	**18,559**	**25,304**
TOTAL ASSETS	**133,226**	**123,189**
EQUITY AND LIABILITIES		
Equity		
Restricted equity		
Share capital	23,451	11,712
Fund for development costs	110,972	94,190
	134,422	**105,902**
Unrestricted equity		
Share premium	185,043	166,264
Retained result	-175,090	-141,828
Result for the year/period	-20,553	-16,480
	-10,600	**7,956**
Total equity	**123,823**	**113,858**
Long term liabilities		
Other long term liabilities	800	800
	800	800
Current liabilities		
Accounts payable	2,674	2,493
Other current liabilities	3,023	3,413
Accrued expenses and prepaid income	2,906	2,625
	8,604	**8,531**
TOTAL EQUITY AND LIABILITIES	**133,226**	**123,189**

Change in equity, condensed

(TSEK)

Jan - Dec 2024 12 months	*Share capital*	*Fund for development costs*	*Share premium*	*Retained result incl. result for the year*	*Total equity*
At the beginning of the period	**11,712**	**94,190**	**166,264**	**-158,308**	**113,858**
Share issue	11,739	0	28,432	0	40,171
Transaction costs, share issue	0	0	-9,653	0	-9,653
Transfer within equity	0	16,781	0	-16,781	0
Net result for the period	0	0	0	-20,553	-20,553
At the end of the period	**23,451**	**110,972**	**185,043**	**-195,642**	**123,823**

(TSEK)

Jan - Dec 2023 12 months	*Share capital*	*Fund for development costs*	*Share premium*	*Retained result incl. result for the year*	*Total equity*
At the beginning of the period	**8,526**	**74,586**	**144,645**	**-122,224**	**105,533**
Share issue	3,186	0	23,098	0	26,284
Transaction costs share issue			-1,479		-1,479
Transfer within equity		19,604		-19,604	0
Net result for the period				-16,480	-16,480
At the end of the period	**11,712**	**94,190**	**166,264**	**-158,308**	**113,858**

Cash flow statement, condensed

(TSEK)	2024-10-01 2024-12-31 3 months	2023-10-01 2023-12-31 3 months	2024-01-01 2024-12-31 12 months	2023-01-01 2023-12-31 12 months
OPERATING ACTIVITIES				
Result after financial items	-6,563	-4,731	-20,553	-16,480
Cash flow from operating activities before change in working capital	**-6,563**	**-4,731**	**-20,553**	**-16,480**
Cash flow from change in working capital				
Increase (-)/Decrease (+) in operating receivables	-63	-2,126	215	-1,976
Increase (+)/Decrease (-) in operating liabilities	-250	1,592	73	3,243
Cash flow from operating activities	**-6,876**	**-5,265**	**-20,265**	**-15,213**
Investing activities				
Acquisition of intangible fixed assets	-5,302	-5,614	-16,781	-19,604
Cash flow from investing activities	**-5,302**	**-5,614**	**-16,781**	**-19,604**
Financing activities				
Share issue	0	0	40,171	26,284
Transaction costs share issue	0	0	-9,653	-1,479
Cash flow from financing activities	**0**	**0**	**30,517**	**24,805**
Cash flow for the period	**-12,178**	**-10,879**	**-6,529**	**-10,012**
Cash and cash equivalents at the beginning of the period	**27,674**	**32,905**	**22,026**	**32,038**
Cash and cash equivalents at the end of the period	**15,496**	**22,026**	**15,496**	**22,026**

The share

Alzinova's share was listed on the Spotlight Stock Market (formerly Aktietorget) on November 25, 2015. As of March 11, 2019, the Company is listed on the Nasdaq First North Growth Market in Stockholm. There is one class of shares in the Company. The share entitles to one (1) vote per share. Each share carries an equal right to a share in the Company's assets and results. As of December 31, 2024, the number of shares in Alzinova amounted to 89,165,460 (44,531,265 as of December 31, 2023).

Largest owners per December 31, 2024

Owner	*Number of shares*	*Capital %*
Försäkrings AB Avanza Pension	15,262,718	17.12%
Maida Vale Capital AB	14,632,418	16.41%
Nordnet Pensionsförsäkring AB	3,117,077	3.50%
Futur Pension	2,850,517	3.20%
Hunter Capital AB	2,222,222	2.49%
Patrik Ahlvin	1,900,000	2.13%
Özlem Erdogdu Gül	1,414,500	1.59%
Ålandsbanken	1,340,954	1.50%
Sara Gjertz	1,140,000	1.28%
Moll Invest AB	1,051,990	1.18%
Totalt de tio största ägarna	**44,932,396**	**50.39%**
Totalt övriga ägare	44,233,064	49.61%
Totalt samtliga ägare	**89,165,460**	**100%**

Stock exchange	Ticker	Listed since
Nasdaq First North Growth Market	*ALZ*	*2015*

Currently there are no long-term share-based incentive programs in the Company. There are no dilution effects regarding the number of shares.

Financial calendar

Annual report, 2024	24 April 2025
Interim report 1, 2025	15 May 2025
Annual General Meeting, 2025	28 May 2025
Half-year report, 2025	21 August 2025
Interim report 3, 2025	13 November 2025
Year-end report, 2025	26 February 2026

Contact

Tord Labuda, CEO
tord.labuda@alzinova.com

Erik Kullgren, CFO
erik.kullgren@alzinova.com

or mail directly to info@alzinova.com

Financial reports are available on the Company's web-site www.alzinova.com as of the date of publication.

Glossary, definitions and abbreviations

Aβ42 - amyloid-beta 42	A peptide (part of a protein) produced by the body that can aggregate in the brain and cause Alzheimer's disease.
"Best-in-class"	A product that is considered superior to other competitors in its class, can be compared to 'first-in-class', which refers to being first to market with a product.
Biomarker	A measurable indicator of a state of disease.
Disease-modifying treatment	Treatment that targets the underlying cause of the disease.
EMA	European Medicines Agency.
FDA	The United States Food and Drug Administration.
R&D	Abbreviation for research and development.
IP	Intellectual properties, for example patents.
Monoclonal antibody	A type of antibody, produced in the laboratory from a single clone of immune cells and directed against a specific protein.
Oligomers	Proteins or peptides, clumped together, used to designate soluble peptide clumps.
Plaque	Local accumulation of clumped insoluble protein, in Alzheimer's mainly consisting of the peptide Abeta42.
Tolerability	The degree of side effects from a medicine that can be tolerated by a patient

Alzinova AB (publ)

Alzinova AB is a Swedish clinical-stage biopharma Company specializing in the treatment of Alzheimer's disease, which focuses on targeting toxic amyloid-beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide™ technology makes it possible to develop disease-modifying treatments that accurately target the toxic amyloid-beta oligomers that are central to the onset and progression of the disease. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases. It is estimated that more than 30 million people in the world today have Alzheimer's disease and the number is expected to triple by 2050. Based on the same technology, the Company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The Company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com

Alzinova AB
Visiting address: Entreprenörsstråket 10, SE-431 53 Mölndal, Sweden
Postal address: Gemenskapens gata 9, SE-431 53 Mölndal, Sweden

alzinova